INBX Inhibrx Biosciences, Inc.
Company Analysis
Latest News
Inhibrx Biosciences, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 13, 2026
Inhibrx Biosciences is expected to report a Q3 2026 loss of $2.50 per share on zero revenue, with the current stock price of $14.82 trading significantly below...
🟢 Inhibrx Biosciences is trading 7.39% up today as major indexes gain more than 1.5%
Inhibrx Biosciences is trading at $91.00, up 7.39% during the November 9 session, with broad-market gains offering a likely sentiment context. - Major indexes...
🟢 Inhibrx Biosciences is trading 5% up today amid biotech-sector gains on Moderna's raised 2026 outlook
Inhibrx Biosciences is trading 5.01% higher at $84.30, with biotech-sector strength providing the clearest available context; no company-specific catalyst has...
🔴 Inhibrx Biosciences is trading 6% down today as biotech weakness adds pressure
Inhibrx Biosciences is trading at $81.43, down 6.14%, amid the November 5, 2026, market sell-off, with biotech weakness adding pressure. - The supplied context...
🟢 Inhibrx Biosciences is trading 6% up today amid biotech-sector and broader-market gains
Inhibrx Biosciences is trading at $84.33, up +5.51%, with sector and broader-market strength a plausible backdrop; no company-specific catalyst was...
🟢 Inhibrx Biosciences is trading 11% up today amid biotech sector strength
Inhibrx Biosciences is trading at $80.02, up 10.89%, amid biotech sector strength. - Biotech (XBI) is up 2.13% as investors rotate away from technology. -...
🟢 Inhibrx Biosciences rises 5.9% — Biotech Stocks Rally on Sector Rotation as Tech Declines
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...